Table 1.
Clinical outcomes and most common AEs (≥ 3 grade).
| Variables | Values | |
|---|---|---|
| Eribulin | Dacarbazine | |
| Clinical efficacy (months) | ||
| Median OS | 15.6 | 8.4 |
| Median PFS | 2.9 | 1.7 |
| Adverse event | ||
| Fatigue | 1.4 | 0.0 |
| Nausea | 1.4 | 0.0 |
| Pyrexia | 0.0 | 1.4 |
| Anaemia | 5.7 | 11.1 |
| Asthenia | 2.9 | 4.2 |
| Peripheral sensory neuropathy | 2.9 | 0.0 |
| Decreased appetite | 1.4 | 2.8 |
| Abdominal pain | 0.0 | 2.8 |
| Vomiting | 0.0 | 1.4 |
| Diarrhoea | 1.4 | 2.8 |
| Dyspnoea | 1.4 | 0.0 |
| Back pain | 2.9 | 0.0 |
| Peripheral oedema | 0.0 | 1.4 |
| Urinary tract infection | 4.3 | 1.4 |
| Laboratory abnormality | ||
| Neutropenia | 27.1 | 15.3 |
| Hypokalaemia | 2.9 | 2.8 |
| Leukopenia | 10.0 | 2.8 |
| Thrombocytopenia | 0.0 | 11.1 |